OctoPlus signs service contract with Axentis Pharma
(Thomson Reuters ONE) - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), thedrug delivery company, announces today that it has signed apharmaceutical development and manufacturing contract with a newclient, Swiss-based Axentis Pharma AG. The undisclosed contract valuecontributes to OctoPlus' annual revenues, for which the Companyreiterates its guidance of ? 19 million.Under the contract terms, OctoPlus will perform process developmentand clinical manufacturing of Axentis Pharma's lead product, which isan inhalable liposomal formulation of tobramycin for the treatment ofcystic fibrosis.OctoPlus provides formulation development and clinical materialmanufacturing services to biotech and pharmaceutical companiesworldwide. In addition to its expertise in formulation andmanufacturing, OctoPlus offers its clients drug delivery technologiesfor the development of controlled release versions of existing or newdrugs.For further information, please contact:Rianne Roukema, Corporate Communications: telephone number +31 (71)524 1071 or send an e-mail to Investor Relations at IR(at)octoplus.nl.About Axentis Pharma AGAxentis Pharma is a respiratory specialty pharmaceutical companywhose core competence is the combination of a fully patented,liposome-based drug delivery system with already established andwell-characterised therapeutic agents. The company is using itsplatform delivery technology, named Fluidosomes(TM) technology, forthe development of its lead product, an inhalable liposomalformulation of tobramycin. Axentis Pharma's lead product is designedto treat bacterial infections in the lungs. For more information onAxentis Pharma, please visit www.axentispharma.com.About OctoPlusOctoPlus is a product-oriented biopharmaceutical company committed tothe creation of improved pharmaceutical products that are based onOctoPlus' proprietary drug delivery technologies and have fewer sideeffects, improved patient convenience and a better efficacy/safetybalance than existing therapies. Rather than seeking to discovernovel drug candidates through early stage research activities,OctoPlus focuses on the development of long-acting, controlledrelease versions of known protein therapeutics, other drugs, andvaccines on behalf of its clients.The clinically most advanced product incorporating our technology isBiolex Therapeutics' lead product Locteron®, a controlled releaseformulation of interferon alpha for the treatment of chronichepatitis C. OctoPlus licensed Locteron exclusively to Biolex inOctober 2008. Locteron is being manufactured for Biolex by OctoPlusand is currently in Phase IIb clinical studies.In addition, OctoPlus is a leading European provider of advanced drugformulation and clinical scale manufacturing services to thepharmaceutical and biotechnology industries, with a focus ondifficult-to-formulate active pharmaceutical ingredients.OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under thesymbol OCTO. For more information about OctoPlus, please visit ourwebsite www.octoplus.nl.This document may contain certain forward-looking statements relatingto the business, financial performance and results of OctoPlus andthe industry in which it operates. These statements are based onOctoPlus' current plans, estimates and projections, as well as itsexpectations of external conditions and events. In particular thewords "expect", "anticipate", "predict", "estimate", "project","plan", "may", "should", "would", "will", "intend", "believe" andsimilar expressions are intended to identify forward-lookingstatements. We caution investors that a number of important factors,and the inherent risks and uncertainties that such statementsinvolve, could cause actual results or outcomes to differ materiallyfrom those expressed in any forward-looking statements. In the eventof any inconsistency between an English version and a Dutch versionof this document, the English version will prevail over the Dutchversion.http://hugin.info/137076/R/1340952/320588.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 14.09.2009 - 07:30 Uhr
Sprache: Deutsch
News-ID 5746
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 314 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus signs service contract with Axentis Pharma"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
